Skip to main content
. 2022 Mar;192(3):484–502. doi: 10.1016/j.ajpath.2021.11.008

Figure 7.

Figure 7

Leptin-neutralizing antibody (Leptin-Ab) attenuates serum transaminases and biliary hyperplasia in multidrug resistance protein 2 knockout (Mdr2KO) mice. A–C: Serum transaminases alanine aminotransferase (ALT; A) and aspartate aminotransferase (AST; B) and hematoxylin and eosin staining (C) of liver sections were assessed for Mdr2KO and FVB/NJ (FVBN) mice treated with vehicle or Leptin-Ab. D–F: Hepatic expression of cytokeratin (CK) 19 mRNA (D) and protein (images in E, quantifications in F) was assessed. E: All arrows point to cholangiocytes (Cs). G–I: Cell proliferation marker, proliferating cell nuclear antigen (PCNA), was assessed at mRNA (G) and protein level, and immunohistochemical (IHC) images (H) and quantification (I) are shown. H: Arrows point to different types of cells expressing PCNA. N = 6 (A, B, D, F, G, and I). ∗P < 0.05 for leptin versus vehicle; †P < 0.05 for Mdr2KO versus FVBN mice. Scale bars = 100 μm (C, E, and H). H, hepatocyte; S, hepatic stellate cell.